Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of SHR-1703 in Subjects With Eosinophilic Granulomatosis With Polyangiitis （EGPA） [Phase 2, Phase 3]

View source ↗

Summary

The entry indicates that Phase 2 and Phase 3 trials are evaluating SHR-1703 for efficacy and safety in eosinophilic granulomatosis with polyangiitis (EGPA).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Eosinophilic Granulomatosis with Polyangiitis

Drugs mentioned

• SHR-1703

Snippet

Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd | Conditions: Eosinophilic Granulomatosis With Polyangiitis | Phase 2, Phase 3 | Status: RECRUITING